-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Answering the Call for Cures in Michigan
This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >
Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum
The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >
BIO Investor Forum Company Snapshot: Syntrix Biosystems
1. What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine. Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2. What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >
BIO Urges Comprehensive Tax Reform
Earlier this week, the Treasury Department issued a notice of its intent to propose rules to limit corporate inversions. In response, we are urging Congress and the Administration to reform the corporate tax system in order to maintain America’s global competitiveness, sustain and create American jobs, and encourage investments in the United States. The U.S. has one of the highest effective corporate tax rates in the world. Current U.S. corporate tax laws, including the lack Read More >
Members of Congress Agree: Reg A+ Rules Need National Standard
We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >
